



Jubilant Ingrevia Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

www.jubilantingrevia.com

PRESS RELEASE

Noida, Tuesday, May 16th, 2023

JUBILANT INGREVIA – Q4 & FY23 RESULTS

Particulars ¹	Q4'FY22	Q4'FY23	Y-o-Y	FY22	FY23	Y-o-Y
Total Revenue	1,296	1,145	-12%	4,949	4773	-4%
Total EBITDA	152	111	-27%	863	580	-33%
EBITDA Margin (%)	11.7%	9.7%		17.4%	12.2%	
Profit After Tax	69	52	-24%	477	308	-35%
Profit After Tax Margin (%)	5.3%	4.6%		9.6%	6.4%	
Basic and Diluted EPS (Rs.)	4.3	3.3	-24%	30.0	19.3	-35%

The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter and year ended March 31st, 2023. The Board of Directors at its meeting held on 16th, May, 2023 has declared a final dividend of Rs. 2.50 per share of Rs. 1 each amounting to Rs. 39.8 Crores. During the year company has already declared an interim dividend of 250% i.e. Rs. 2.5 per equity share of Rs 1 each and the total dividend for FY'23 works out to be 500% i.e Rs 5.0 Per equity share of Rs 1 each amounting to Rs 79.6 Crore of Cash outflow.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said:

*"We are happy to announce that during the year FY23 our **Specialty chemicals business grew 29%**, **Chemical Intermediate business placed highest ever volume of Acetic Anhydride** and gained higher market share globally, however Nutrition business have faced headwinds for Niacinamide leading to lower volume as well as lower price realization. EBIDTA in FY'23 was lower mainly on account of higher energy prices and challenging market situation of Niacinamide business.*

*During the quarter, though our **Specialty Chemicals business** recorded higher revenue and **Chemical Intermediate business** have placed higher volume of Acetic Anhydride YoY, however **overall revenue** was lower due to lower price of Acetic Acid leading to lower price of Acetic Anhydride and the headwinds we continue to face in Niacinamide business. Though EBIDTA during the quarter for Chemical Intermediate business improved YoY however overall EBIDTA performance impacted due to challenging market situation of Niacinamide and some of our Specialty products meant for Agrochemicals customers.*

*We firmly believe that the challenges faced in **Niacinamide business** and in some of our **products in Specialty Chemical meant for Agrochemical customers** are of short-term nature, and business is confident to regain volumes, revenue and profitability as market situation improves.*

Our endeavors towards our growth plans remains undeterred, through our structured growth capex and we are confident about delivering robust growth in the future, this growth will be led primarily through our Specialty Chemicals & Nutrition Business segment

We are also glad to share that the Board has recommended a final dividend of 250% i.e. Rs 2.5 per equity share of face value of Re 1 each for the FY'23. This shall result in cash outflow of Rs 39.8 Crore. During the year company has already declared an interim dividend of 250% i.e. Rs. 2.5 per equity share of Rs 1 each and the total dividend for FY'23 works out to be 500% i.e. Rs 5.0 Per equity share of Rs 1 each amounting to Rs 79.6 Crore of Cash outflow."



Q4 & FY23 Highlights | Segment Wise Analysis

A. Speciality Chemicals

Particulars ¹	Q4'FY22	Q4'FY23	Y-o-Y	FY22	FY23	Y-o-Y
Segment Revenues	444	468	5%	1,393	1798	29%
% Contribution to Revenues	34%	41%		28%	38%	
EBITDA	81	55	-32%	312	284	-9%
% EBITDA Margins	18%	12%		22%	16%	
% Contribution to EBITDA	53%	50%		36%	49%	

- Business recorded good revenue growth in FY23 led by healthy volume growth.
- Segment EBITDA & Margins during the year were impacted due to high Energy cost and headwinds faced in some of the Specialty products meant for Agrochemical customers
- Demand impact of products meant for Agrochemicals customers is of short-term in nature and should start improving by end of Q2'FY24.
- Business continues witnessing positive traction in CDMO products.
- New cGMP multipurpose plant in Bharuch and Non-GMP plant in Gajraula is commissioned, this will aid in volume and revenue growth of CDMO business in coming quarters.
- Higher capacity utilization of existing and new plants coupled with new product pipeline thru new growth capex will enable future growth in Specialty chemical.

B. Nutrition & Health Solutions

Particulars ¹	Q4'FY22	Q4'FY23	Y-o-Y	FY22	FY23	Y-o-Y
Segment Revenues	206	155	-24%	767	551	-28%
% Contribution to Revenues	16%	14%		16%	12%	
EBITDA	50	5	-90%	164	46	-72%
% EBITDA Margins	24%	3%		21%	8%	
% Contribution to EBITDA	33%	4%		19%	8%	

- Business during the year impacted due to Avian and Swine Flu in EU and US regions, resulting into lower volume and significant price erosion of Niacinamide (Vitamin B3).
- Niacinamide volumes improved sequentially during Q4.
- Expect improvement in Niacinamide global demand.
- Domestic business of Choline Chloride(Vitamin B4) continues to maintain its market leadership.
- Approved new cGMP compliant facility for producing Cosmetic grade Niacinamide during the quarter.
- Development work of new cGMP compliant capacity for Food grade Vitamin B4 (i.e Choline Chloride & Choline Bitartrate) is on track. We expect to approve this capex soon.

C. Chemical Intermediates Segment

Particulars ¹	Q4'FY22	Q4'FY23	Y-o-Y	FY22	FY23	Y-o-Y
Segment Revenues	646	522	-19%	2,789	2423	-13%
% Contribution to Revenues	50%	46%		56%	51%	
EBITDA	30	59	98%	417	283	-32%
% EBITDA Margins	5%	11%		15%	12%	
% Contribution to EBITDA	20%	53%		48%	49%	

- Revenue of the year is lower on account of lower feed stock prices i.e. Acetic Acid, leading to lower price realization of both Acetic Anhydride & Ethyl Acetate.
- EBITDA for the year is lower due to normalization of Acetic Anhydride market situation leading to normalization of price.
- Business continues to place higher volumes in global market, enhancing market share of Acetic Anhydride globally.
- Outlook for Acetic Anhydride market appears to be stable, Global demand continues to grow in several end-use segments.
- Business continues to rationalize sales of Ethyl Acetate and Specialty Ethanol to niche customers.
- Successfully commissioned New Acetic Anhydride plant in Bharuch.

D. Income Statement – Q4 & FY23

Particulars ¹	Q4'FY22	Q4'FY23	YoY	FY22	FY23	YoY
Revenue from operations						
a) Sales/Income from operations	1276	1129	-11%	4914	4740	-4%
b) Other operating income	20	16	-22%	35	32	-8%
Total revenue from operations	1296	1145	-12%	4949	4773	-4%
Other income	9	9	-2%	31	33	6%
Total income	1305	1154	-12%	4981	4806	-4%
Expenses						
a) Cost of materials consumed	717	545	-24%	2844	2548	-10%
b) Purchases of stock-in-trade	40	54	37%	141	162	15%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	23	49	107%	-145	-128	-12%
d) Employee benefits expense	82	86	5%	327	343	5%
e) Finance costs	6	6	-7%	31	22	-30%
f) Depreciation and amortisation expense	31	30	-3%	123	122	-1%
g) Other expenses:						
- Power and fuel expense	145	150	4%	468	709	51%
- Others	146	159	8%	482	591	23%
Total expenses	1190	1078	-9%	4272	4369	2%
Profit before tax	115	76	-34%	709	437	-38%
Tax expense						
- Current tax	17	12	-31%	125	70	-44%
- Deferred tax charge	29	12	-60%	107	59	-45%
Net profit for the period/year	69	52	-24%	477	307	-35%
Earnings per share of ₹ 1 each (not annualised except for 31 March 2022)						
Basic (₹)	4.3	3.3	-24%	30.0	19.3	-35%
Diluted (₹)	4.3	3.3	-23%	30.0	19.3	-36%

1. All figures are in Rs Crore unless otherwise stated

E. Segment P&L - Q4 & FY23

Particulars ¹	Q4'FY22	Q4'FY23	YoY (%)	FY22	FY23	YoY (%)
Total Revenue from Operations	1,296	1,145	(12%)	4,949	4,773	(4%)
Speciality Chemicals	444	468	5%	1,393	1,798	29%
Nutrition & Health Solutions	206	155	(24%)	767	551	(28%)
Chemical Intermediates	646	522	(19%)	2,789	2,423	(13%)
Reported EBITDA	152	111	(27%)	863	580	(33%)
Speciality Chemicals	81	55	(32%)	312	284	(9%)
Nutrition & Health Solutions	50	5	(90%)	164	46	(72%)
Chemical Intermediates	30	59	98%	417	283	(32%)
Unallocated Corporate (Expense)	-10	-8	-	-30	-32	6%
PAT	69	52.31	(24%)	477	308	(35%)
EPS	4.3	3.3	(24%)	30.0	19.3	(35%)
Reported EBITDA Margins	11.7%	9.7%		17.4%	12.2%	
Speciality Chemicals	18.2%	11.9%		22.4%	15.8%	
Nutrition & Health Solutions	24.4%	3.1%		21.4%	8.3%	
Chemical Intermediates	4.6%	11.3%		14.9%	11.7%	
Net Margin	5.3%	4.6%		9.6%	6.4%	

F. Balance Sheet & Key Ratios

Particulars ¹	31-Mar-22	31-Mar-23
Shareholders Fund	2,433	2,666
Non Current liabilities	311	413
Long Term Borrowings	100	150
Other Long Term Liabilities	212	263
Current Liabilities	1,053	1,180
Short Term Borrowings	129	247
Trade Payables	772	778
Other Current Liabilities	152	154
Total	3,797	4,259
Non Current Assets	2,033	2,441
Net Fixed Assets	1,745	1,788
Non Current Investments	3	3
Other Assets	284	650
Current Assets	1,765	1,818
Inventories	911	1,035
Trade Receivables	581	511
Cash, Bank & Investments	49	85
Other Assets	224	187
Total	3,797	4,259

Key Ratios

Particulars ¹	FY'2022	FY'2023
Net Debt	181	312
Net Debt to Equity	0.07x	0.12x
Net Debt to EBITDA	0.21x	0.54x
Working Capital to Turnover	16%	17%



About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

The Company offers a broad portfolio of high quality ingredients that find application in a wide range of industries. The company has over 2,100 employees and serves more than 1,500 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.

For more information, please visit: www.jubilantingrevia.com.

For more information, please contact:

For Investors

Pavleen Taneja
Jubilant Ingrevia Limited
Ph: +91-120 436 1000
E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya
Ph: +91-120 436 1062
E-mail: sudhakar.safaya@jubl.com

Clayton Dsouza
Madison Public Relations
E-mail: clayton.dsouza@madisonpr.in
Ph: +91 9930011602

Earnings Call details: The company will host earnings call at 5.00 PM IST on 16th May, 2023

Diamond Pass Log-In	
Pre-registration:	To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.  Click here to Express/Join the Call You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.
Conference Dial-In Numbers	
Universal Access:	+ 91 22 6280 1141 + 91 22 7115 8042
Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Replay Facility:	Available from May 16 to May 23 Dial in No.: +91 22 7194 5757 Playback ID: 92052#



Disclaimer:

Note 1

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.